A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when
A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when Voxelannounced that it believed its current vendorlaser systemdeveloper General Scanningwas in breach of contract for allegedlyfailing to meet engineering specifications and delivery datesfor the Voxcam imager, a central element in Voxel's digital holographysystem (SCAN 1/22/97).
The dispute between Voxel and General Scanning, of Watertown,MA, is now headed for binding arbitration. Meanwhile, Voxel hasdecided to accelerate its alternative manufacturing program dueto several factors, such as tests by the company that Voxel believesconfirm the engineering shortcomings at the root of its disputewith General Scanning. Under its contract with General Scanning,Voxel had been prohibited from using another manufacturing partner,but that provision was waived when the dispute went to arbitration.
Voxel's alternative manufacturing program will include securingsubsystems from qualified vendors and will also include performingfinal assembly and testing in-house for a pilot production run.A system integrator for volume manufacturing will also be selected.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.